Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A bit of light reading....
I wouldn't read anything in to it- many clinical studies go months (or even years) without an update.
The rate-limiting factor is not "reluctance" per se, but the stringent subject selection criteria (limited to lifelong PE according to the ISSM definition, with a population prevalence of only a few percent, plus a raft of other exclusions), hence the need for a relatively large number of sites (18 listed) to recruit for what is after all a small (100 subject) pilot study.
i hope it is not indicative of a problem recruiting but if it is it may,unfortunately,simply be symptomatic of the problem alluded to below of resistance and reluctance to come forward with PE.let us hope its just the usual regent inability to progress things with celerity and drive lol!
as to why people should buy now i completely agree.who in their right mind would buy without knowing what the new project/next big thing is going to be and without seeing the effect of the dilution.of course there has in reality been hardly any buying of any volume for a while which is hardly surprising.still hoping that we get a new board member to breathe some life into things here
Since there has still not been any update on the gov website since the 10th May (nearly 12 weeks ago), does this indicate they are having problems recruiting ???
That's correct. All the shares wont hit the market at the same time, but it will eventually be 17.5mill usd worth at 0.215 (including the 4% interest shares).
According to the convertible notes announcement the company has already been lent 5.5mill usd and they still have the ATO settlement sum of 6.73 mill USD to pay, which I am sure will not come out of the already loaned monies since huge salaries still need to be paid as well as the continued FDA approval process and all office costs etc. If that is the case, the shares could be as much as 12.23million USDs worth which adds up to about 17.5% dilution. Anyway, we will soon find out if this is the case.
interesting post bignose re USA and ED.let us hope that as FDA application progresses we see an increase in interest.
Might it be that the new shares being issued to the new investors will not necessarily "hit the market" but be held by the new investors?
I really don't understand why anyone would be buying now with all the new shares that will be hitting the market ? are Brokers being so unprofessional as to not advise those buying to wait till the **** hits the fan ??? Or is it just a case of who gives a fcuk, "Hand us your money"....... :-O
Although only about ED, the below discussion does reflec the same issues associated with PE:
PDE5is have certainly helped break down the taboo around erectile dysfunction – at least in the US. In the US, direct to consumer advertising of Cialis and Viagra over a number of years has increased awareness of the condition and broken down barriers to discussing it. It’s no accident that around 50-60% of the ED market is in the US.
It’s a different story in the UK. We had a very interesting meeting with a sexual therapist here who said that the attitudes in the UK towards erectile dysfunction are almost Victorian (seems to be the same in Europe too). It’s not ‘manly’ to want to seek help. It’s a more difficult prejudice to break down in this market.
Also, if you look at the researchers, the key opinion leaders and the pharma workers in this area, you’ll see that there are very few women involved in the discussion. One of the growing fields within sexual medicine is female sex, and it’s also a problem for the female if the male can’t perform as the women feel unattractive and inadequate. In some cases it can have a devastating effect on a partnership or marriage. We’re trying to get a much better understanding of that, and look at this as something that doesn’t just impact the male in a relationship.
One would think that ED would have already broken down barriers with respect to discussing other Sexual problems, although it certainly appears not to. I guess its easier to discuss if a man has or hasn't wood as appose to "the horse has already bolted from the gate"... ;-)
As I previously speculated. Without the main shareholders who are involved in the placing, just under 1.6% of the company voted FOR. I wonder who they were ? I would guess a few of the remaining BOD and company employees (instructed to vote or start looking for a job).
Interims released this pm, bigs up the recent rare disease acquisitions and underscore the commitment to orphan/rare disease expansion (both by portfolio and geography).
Still apparent growth in Urorec revenue, although not clear whether this is through volume or price increase, but might mean that the urology field force in mature markets may not be wound down immediately.
i'll second that!
Some good news wouldn't go a miss.
all resolutions duly passed so we move on to the next stage.news of aussie tax payment by end of week?
With this share roosters i think you were right the first time with worrier :D :D
Hello Bignose. Could you give JM an email and see what he says to you please?
afternoon bignose.completely agree.looked like we were heading towards 0.215 but actually ended with more buys than sells.usual low volume so really just drifting.keith asks (rhetorically i suspect )for reasons and one i think is that which you have mentioned several times and its the failure to address the likely negative effect on sales of reluctance to seek treatment through embarrassment etc. i think we all realised this was going to be a factor but felt it was trumped by the sheer number of potential sufferers and the wide market.you have rightly criticised the board for carrying out insufficient market research and by implication taking too roseate a view of prospects.constant failure to adhere to time lines etc hasnt helped nor has the slow progress re FDA .i know I'm just repeating what has already been said many times so apologies for that.i really do hope we get some new blood on the BOD as a transfusion is sorely needed.will be relieved when the CLNs go through as at least it will give some breathing space for the next stage ,whatever it may be, to develop.
Hopefully it will stop when it reaches 0.215, but then again.... As there is nothing to offer shareholders old or new, it could just go lower. JG should be ashamed of himself. And the BOD should be removed for recommending his 1.5million USD salary, although he is certainly doing a good job in lowering shareholder value.......Wait a minute....Maybe that's why he is being paid so much. I mean all he has done is reduced the companies value since the PLE takeover.
Headless chickens come to mind......lol.
sorry ..warrior 1066
As always,TheItalian, a very erudite and salient post. I totally agree with you that they seem to be playing ‘catch the next big thing’ without actually knowing what they are doing. I still have problems understanding where it all went wrong with Fortacin. When I invested I genuinely believed that it was a product with saleability if not the ‘money fountain’ prophesied. I would be happy to get out now with even money!??
thanks worrier ,il check them out
roosters SAXO international could possibly help
keithbfk and bignose i completely agree with you.i hope we are all wrong but as i posted before they seem to be flailing around without reel direction.as you say bignose yooya would have given them an online retailing position and this was why i was feeling quite positive about it as i hoped it would give them a fairly immediate source of revenue albeit small to start with which would have helped with the cash position. they would have needed to source products but that seemed to be part of the plan.as you say its not at all clear what they have in mind here and it does smack of chasing the next big thing.there are i gather a great many cbd producers so I'm feeling bit of deja vu as its reminiscent for me of the dotcom bubble and the plethora(sorry) of would be internet service providers most of whom disappeared without trace.hope I'm wrong but i entirely agree that even if they get into a potentially profitable niche do they have the abilities and competencies to bring it off?glad no announcement today so presumably this means the CLNs are still on track and I'm hopeful that abony will still be put on the board and that Costanzo will take some interest as an investor.costanzo worked for uber and is probably used to seeing results delivered so lets hope for a culture shock for jamie and a shake up of the applecart.does this new approach tie in with the "already identified and significantly diligenced (arghh!) acquisition and investment opportunities" already referred to in the circular?perhaps not as this seems a different area of operation but we need more detail.
rooster not sure if this is any help but have you tried contacting HSBC.i think they have specialist hong kong dealing services.not sure how helpful they would be for a one off and in certificated form but they may be able to point you in the right direction
I have 1.8 million shares in rpg from the original investment in plethora, im about to retire , these were supposed to prop up my pension but there worth a fraction of cost , I hold these in certificate form at home , any ideas how I can sell them now as HL don't trade in hk ?thanks in advance